Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00810147 · ClinicalTrials.gov registry record · Phase 2
A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease
A Phase 2 study of Alzheimers Disease, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 209
- Enrollment target
- 20
- Study locations
NCT00810147 is a Phase 2 study of Alzheimers Disease that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 209 participants, below the 4,060-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT00810147, a Phase 2 study of Alzheimers Disease, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 209 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety and tolerability of BMS-708163 in patients with mild to moderate Alzheimer's disease over a treatment period of 12-weeks and the course of any potential effects during a 12-week wash-out period
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BMS-708163
Study Locations (20)
Florida
- Meridien Research - Brooksville
- Brain Matters Research - Delray Beach
- Md Clinical - Hallandale
- Compass Research, Llc - Orlando
- Miami Research Associates - South Miami
- Usf Suncoast Alzheimer'S And Gerontology Center - Tampa
- Center For Clinical Trials - Venice
California
- Margolin Brain Institute - Fresno
- Collaborative Neuroscience Network, Inc. - Garden Grove
- Pacific Institute For Medical Research, Inc. - Los Angeles
- Mary S. Easton Center - Los Angeles
- Pacific Research Network, Inc - San Diego
- California Neuroscience Research Medical Group, Inc. - Sherman Oaks
Arizona
- 21st Century Neurology - Phoenix
- Banner Alzheimer'S Institute - Phoenix
- Sun Health Research Institue - Sun City
Connecticut
- Yale University School Of Medicine - New Haven
- Comprehensive Psychiatric Care - Norwich
Alabama
- University Of Alabama At Birmingham - Birmingham
Indiana
- Indiana University Medical Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00810147
The ClinicalTrials.gov registry entry for NCT00810147 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 209 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,060-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (95% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00810147 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00810147 about?
NCT00810147 is a clinical study titled "A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease". The purpose of this study is to determine the safety and tolerability of BMS-708163 in patients with mild to moderate Alzheimer's disease over a treatment period of 12-weeks and the course of any potential effects during a 12-week wash-out period
What is the current status of trial NCT00810147?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 209 participants. The study started on 2009-02. Estimated completion is 2010-06.
What conditions does trial NCT00810147 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT00810147?
The interventions under investigation include: Placebo (DRUG), BMS-708163 (DRUG).
Who is sponsoring clinical trial NCT00810147?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00810147 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.